Performance comparison between heterologous and homologous COVID19 vaccine schedules on Omicron variant incidence: A real-world retrospective cohort study in Southern Italy

• DOI: 10.1016/j.vaccine.2023.07.055
• Publication Date: 2023-08-09T20:01:32Z
• Authors: Francesco Baglivo; Mariano Magrì; Luigi De Angelis; Valerio Aprile; Martina Minelli; Raffaele Stifini; Pierluigi Lopalco; Caterina Rizzo; Alberto Fedele
• Keywords: Heterologous; Booster dose; Vaccination schedule; Booster (rocketry)

As the COVID19 pandemic progresses, there is an increasing need to evaluate performance of vaccine strategies. This study investigated schedule heterologous vaccination compared homologous in preventing Omicron SARS-CoV2 infection adult population. retrospective cohort utilized data from Infections Regional Information System and Apulia Vaccine Registry identify individuals who received a booster dose one 14 different schedules between September 2021 August 2022 province Lecce, Southern Italy. The standardized cumulative incidence after was assessed risk subgroups using Cochran-Mantel-Haenszel test. A total 469,069 subjects were included study. varied greatly among schedules, with highest lowest being AZ-AZ-BNT (34.7 %) MOD-MOD-BNT (18.9 %), respectively, some performing better than ones. significantly lower specific best common odd ratio 0.661 (IC. 95 % [0.620-0.704]). provides evidence that may be more effective highlighting how product, rather platform, involved protection provided by vaccination.